Abstract
Adoptive cell therapy using cytotoxic CD8+ T lymphocytes (CTL) has shown promising results in recent clinical trials for cancer patients. Although significant advances have been achieved in this field, there are still many issues that need to be addressed before wide application of adoptive cellular immunotherapy as an adjuvant or mainstream therapy for various cancers. Difficulties related to the ex vivo generation of large number of effective antigen-specific CTLs, their in vivo tracking and short term survival following adoptive transfer are among the barriers decelerating the clinical use of this approach. In this review, we focus on recent developments in adoptive cell therapy using CD8 T cells and discuss the hurdles that need to be overcome. In addition, current status of adoptive cell transfer using other T cell populations for cancer immunotherapy that may circumvent some of the problems related to current protocols of using CTL is also discussed.
Keywords: Adoptive Cell Transfer, Chronic Myeloid Leukemia, Tumor Infiltrating Lymphocytes, Hematopoietic Stem Cell Transplantation, Peripheral Blood
Current Cancer Therapy Reviews
Title: Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Volume: 4 Issue: 1
Author(s): Li Zhang and Pouneh Dokouhaki
Affiliation:
Keywords: Adoptive Cell Transfer, Chronic Myeloid Leukemia, Tumor Infiltrating Lymphocytes, Hematopoietic Stem Cell Transplantation, Peripheral Blood
Abstract: Adoptive cell therapy using cytotoxic CD8+ T lymphocytes (CTL) has shown promising results in recent clinical trials for cancer patients. Although significant advances have been achieved in this field, there are still many issues that need to be addressed before wide application of adoptive cellular immunotherapy as an adjuvant or mainstream therapy for various cancers. Difficulties related to the ex vivo generation of large number of effective antigen-specific CTLs, their in vivo tracking and short term survival following adoptive transfer are among the barriers decelerating the clinical use of this approach. In this review, we focus on recent developments in adoptive cell therapy using CD8 T cells and discuss the hurdles that need to be overcome. In addition, current status of adoptive cell transfer using other T cell populations for cancer immunotherapy that may circumvent some of the problems related to current protocols of using CTL is also discussed.
Export Options
About this article
Cite this article as:
Zhang Li and Dokouhaki Pouneh, Recent Advances in T Cell Adoptive Immunotherapy of Cancer, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565475
DOI https://dx.doi.org/10.2174/157339408783565475 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Editorial [Hot Topic: Cancer Genetics (Guest Editor: Anirban Maitra)]
Current Molecular Medicine Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Current Drug Safety Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design A Review of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets The Anticancer Activity of the N-Terminal CARD-Like Domain of Arginine Deiminase (ADI) from Pseudomonas aeruginosa
Letters in Drug Design & Discovery A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology